Abstract: The present invention pertains to a combination of specific benzene sulfonamide thiazole compounds with an anticancer treatment for use in the treatment of cancer in a patient who has been identified as overexpressing GRP78. Using a colorectal cancer mice model (CT26 allograft model) and several cancer cell lines models in vitro, the present inventors have shown that a combined therapy using HA15, a benzene sulfonamide thiazole compound, and an anticancer treatment such as an immunotherapeutic agent, a chemotherapeutic agent or targeted therapies significantly improves the survival rate and strongly reduces tumor growth as compared to monotherapies comprising either a benzene sulfonamide thiazole compound or an anticancer agent alone.

Abstract: The present inventors have shown that specific benzene sulfonamide thiazole compounds (I) have the ability to induce an early endoplasmic reticulum stress. These compounds also lead to cancerous cells growth inhibition and death.